Imunon, Inc. (IMNN) Earnings

Management highlights

- Clinical Development Progress • Final phase 2 Ovation 2 trial data for Immunon 001, a proprietary IL-12 immunotherapy for frontline treatment of newly diagnosed advanced ovarian cancer, demonstrated a clinically meaningful 14.7 month median overall survival benefit when combined with standard of care chemotherapy, with a clean, consistent safety profile and unique localized delivery with negligible systemic exposure. • Pivotal phase 3 Ovation 3 trial (enrolling 500 total patients) is advancing on track, with enrollment currently outperforming internal monthly targets, driven by strong investigator enthusiasm (particularly from Ovation 2 participating sites that have observed first-hand clinical benefit) and proactive outreach from new sites globally following public data disclosures. • An R&D Day event is planned for Q3 2026 to showcase final Ovation 2 efficacy analysis, additional safety, efficacy, and translational data from the Ovation 2 trial and the ongoing MRD study, and input from trial investigators and oncology experts. • Final Ovation 2 overall survival results are scheduled for presentation at an upcoming major national oncology conference. - Financing and Capital Strategy • The broader biotech capital funding environment remains challenging, and management is executing a multi-pronged, disciplined strategy to extend cash runway while minimizing shareholder dilution, with the core priority of fully funding the Ovation 3 trial. • Management is pursuing a targeted bridge financing strategy structured to bring the company closer to trial readout to attract new long-term fundamental investors, with creative structures (such as non-warrant preferred shares with delayed trading) designed to limit share price pressure and dilution relative to standard dilutive registered direct offerings. • Management is confident the strong Immunon 001 clinical data will attract minimally dilutive or non-dilutive investment from one or more strategic partners. - Operational Efficiency • A strategic organizational reorganization completed earlier in 2022 has reduced unnecessary overhead and refocused all resources on advancing the Ovation 3 trial, supporting extended operating runway while maintaining trial momentum.

Guidance

- Ovation 3 trial enrollment: Management reaffirms guidance to randomize ~80 patients by the end of Q1 2027, and complete enrollment of all 500 patients by Q1 2029, with current enrollment tracking ahead of internal forecasts. - Operating expense guidance: Following the 2026 strategic reorganization, total quarterly operating spend is projected to be between $4.5 million and $5 million for coming quarters; G&A spending is expected to remain stable at Q1 2026 levels, while R&D spending will increase as more Ovation 3 sites are activated and enrollment accelerates. - R&D Day is confirmed to be held in Q3 2026, with no changes to this timeline. - The trial design includes two planned interim efficacy analyses after full enrollment: the first approximately 12-18 months post-full enrollment, and the second approximately one year after the first. Management is evaluating whether the larger-than-expected survival benefit observed in Ovation 2 could allow for a pulled-forward final analysis, and will provide additional guidance on interim analysis timelines in the future.

Segment performance

Immunion is a clinical-stage biotech company with a single lead product candidate (Immunon 001), so no separate product segments are reported. For Q1 2026: research and development expenses were $2.3 million, compared to $2.2 million in Q1 2025; general administrative expenses remained flat at $2.3 million year-over-year; net cash used for operating activities was $4 million, up from $2.8 million in the prior year quarter, with the increase driven by startup costs for the Ovation 3 phase 3 trial. As of Q1 2026, the company held cash sufficient to support current operations through trial enrollment activities per its disciplined capital planning.

Risks & headwinds

- Full enrollment of the 500-patient Ovation 3 trial and maturation of overall survival data for a BLA filing will take longer than many investors prefer, creating extended time to clinical and regulatory milestone achievement that increases funding requirements and financing risk. - The broader biotech capital funding environment remains challenging, which could impact the company's ability to raise required capital at attractive terms for the company and its existing shareholders. - If enrollment underperformed original projections, that would negatively impact business development discussions, investor sentiment, and the company's ability to advance the trial in a timely manner. - Shifts in the ovarian cancer treatment landscape over the multi-year course of the Ovation 3 trial could introduce competitive changes, though management currently assesses this risk as modest. - Regulatory changes at the FDA could alter approval requirements for new oncology treatments, though management notes the trial's primary endpoint of overall survival is the FDA's current gold standard for oncology efficacy, reducing this risk.

Analyst Q&A

• Q: What gives management confidence in the stated Ovation 3 enrollment timeline, and how has enrollment demand factored into these projections? /

  A: Management confirms 500 total patients will be enrolled, with final last patient enrollment targeted for Q1 2029, and ~80 patients enrolled by Q1 2027. The company is actively increasing the number of activated trial sites this year, and current enrollment has consistently outperformed internal monthly targets. Strong performance is driven by early sites (veteran Ovation 2 investigators) who have directly observed clinical benefit from Immunon 001, leading to higher patient accrual than originally projected.

• Q: How does strong current enrollment impact interest from potential business development partners? /

  A: While enrollment progress and partner interest are separate streams of activity, poor enrollment would have a clear negative impact on BD and investor discussions. Strong enrollment, paired with growing interest from new global sites following Ovation 2 data publication, generates positive momentum that improves all of the company's outreach efforts, including partnership and financing discussions.

• Q: What are the trial design's powering and blinding assumptions for Ovation 3, how might shifting competitive landscape impact the trial? /

  A: Ovation 3 is unblinded for patients and clinicians (agreed by the FDA, as a catheter insertion is required for treatment and sham insertion would be unethical for control patients), though the company maintains internal data access controls to preserve trial integrity. The trial includes two planned interim analyses that allow for early stopping for efficacy. The 14.7-month survival benefit seen in Ovation 2 is far larger than the initial 11-month estimate, and management is evaluating if this allows a pulled-forward final analysis. New second-line ovarian cancer treatments (such as ADCs) are modest advances that do not meaningfully impact the trial, as Immunon 001 targets frontline disease, and its projected >12-month survival benefit is far larger than the small benefits offered by newer second-line agents. Recent restrictions on PARP inhibitor use further highlight the unmet need for effective frontline treatments.

• Q: What is the G&A spending outlook after the recent reorganization, and what is the regulatory path for approval with the new FDA administration? /

  A: Following the reorganization, G&A will remain stable near Q1 2026 levels, with total quarterly operating spend coming in between $4.5 million and $5 million; R&D will rise as Ovation 3 site activation and enrollment accelerate. The FDA has already confirmed no safety concerns with the trial design, and the planned interim analyses allow for full approval if efficacy thresholds are met. Management is focused on full approval rather than accelerated approval, and since the primary endpoint is overall survival (the FDA's current stated gold standard for oncology), recent regulatory shifts do not create material approval risk.